Hannibal Charlotte Gerd, Vang Russell, Junge Jette, Frederiksen Kirsten, Kjaerbye-Thygesen Anette, Andersen Klaus Kaae, Tabor Ann, Kurman Robert J, Kjaer Susanne K
Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, 2100 Copenhagen, Denmark.
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Gynecology & Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gynecol Oncol. 2014 Aug;134(2):267-73. doi: 10.1016/j.ygyno.2014.06.002. Epub 2014 Jun 10.
To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population.
The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013.
A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p=0.3), whereas women with advanced stage disease had a poorer one (p<0.0001). This was evident both in women with noninvasive (p<0.0001) and invasive implants (p<0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p<0.0001) and noninvasive LGSC (p<0.0001) was poorer than expected from the general population.
To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.
描述丹麦25年间浆液性“交界性”卵巢肿瘤(SBT)女性患者的研究人群,并相对于普通人群估计其总生存率。
利用丹麦病理数据库和丹麦癌症登记处,识别出1978年至2002年间被诊断为SBT的1487名女性。从丹麦各病理科收集组织学切片,由专家病理学家进行复查,并分类为SBT/非典型增生性浆液性肿瘤(APST)或非侵袭性低级别浆液性癌(LGSC)。相关种植灶分类为非侵袭性或侵袭性。从医院各科室收集病历并进行复查。采用Kaplan-Meier法进行数据分析,并通过随访至2013年9月2日估计相对生存率。
确定了一组1042名确诊为SBT的女性。I期女性的总生存率与普通人群预期的总生存率相似(p=0.3),而晚期疾病女性的总生存率较差(p<0.0001)。这在有非侵袭性(p<0.0001)和侵袭性种植灶的女性中均很明显。仅在晚期女性中,SBT/APST(p<0.0001)和非侵袭性LGSC(p<0.0001)女性的总生存率低于普通人群预期。
迄今为止,这是全国范围内最大的SBT队列研究,所有肿瘤均经专家病理学家核实。仅晚期SBT女性的总生存率低于普通人群,这适用于有非侵袭性和侵袭性种植灶的女性以及有SBT/APST和非侵袭性LGSC的女性。